SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.388
EU - Europa 724
AS - Asia 258
SA - Sud America 10
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 4.387
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.379
GB - Regno Unito 266
SE - Svezia 136
DE - Germania 105
IT - Italia 84
HK - Hong Kong 65
TR - Turchia 59
CN - Cina 55
VN - Vietnam 45
BG - Bulgaria 30
FI - Finlandia 27
FR - Francia 26
JP - Giappone 11
UA - Ucraina 10
IE - Irlanda 9
IN - India 7
RU - Federazione Russa 6
BR - Brasile 5
BZ - Belize 4
LU - Lussemburgo 4
NO - Norvegia 4
RO - Romania 4
AU - Australia 3
CA - Canada 3
MY - Malesia 3
NL - Olanda 3
SG - Singapore 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
BE - Belgio 2
KR - Corea 2
AT - Austria 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
IQ - Iraq 1
IR - Iran 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 4.387
Salva come PNG Salva come JPEG
Città #
Fairfield 712
Ashburn 357
Seattle 302
Woodbridge 292
Chandler 251
Houston 247
Cambridge 218
Wilmington 216
Southend 210
Dearborn 117
Nyköping 106
Ann Arbor 74
Hong Kong 64
Izmir 58
Dong Ket 44
New York 43
San Diego 43
Princeton 31
Bremen 30
Eugene 30
Sofia 30
London 29
Helsinki 25
Phoenix 25
Modena 18
Beijing 12
Milan 10
Boardman 9
Dublin 9
Jacksonville 9
Tokyo 9
Shanghai 8
Kunming 7
Norwalk 7
Hefei 6
Hanover 5
Belize City 4
Edinburgh 4
Hounslow 4
Nanjing 4
Redwood City 4
San Jose 4
San Mateo 4
Atlanta 3
Bari 3
Florence 3
Gunzenhausen 3
Jinan 3
Oslo 3
Saint Louis 3
São Paulo 3
Treviso 3
Amsterdam 2
Augusta 2
Bologna 2
Brussels 2
Cervignano del Friuli 2
Chicago 2
Clearwater 2
Fuzhou 2
Martinez 2
Melbourne 2
Mumbai 2
Napoli 2
Romainville 2
Saint-Fons 2
Shenyang 2
Turin 2
Aioicho 1
Auckland 1
Bandar Seri Begawan 1
Bangkok 1
Basra 1
Boston 1
Brentford 1
Busto Arsizio 1
Cairo 1
Central District 1
Chisinau 1
Chiswick 1
Cleveland 1
Dallas 1
Denver 1
Distrito Federal 1
Falkenstein 1
Frankfurt am Main 1
Geneve 1
Guangzhou 1
Hangzhou 1
Hanoi 1
Huzhou 1
Hyderabad 1
Iasi 1
Islington 1
Jakarta 1
Jiaxing 1
Kemerovo 1
Kilburn 1
Kish 1
Lamezia Terme 1
Totale 3.782
Salva come PNG Salva come JPEG
Nome #
Immunotherapy for colorectal cancer: where are we heading? 209
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 193
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 188
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 180
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 168
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 168
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 167
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 165
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 161
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 160
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 156
The Italian Rare Pancreatic Exocrine Cancer Initiative 152
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 151
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 149
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 147
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 145
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 144
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 143
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 142
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 141
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 140
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 136
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 136
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 135
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 131
Immunotherapeutic approaches for hepatocellular carcinoma 130
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 127
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 120
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 103
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 92
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 3
Totale 4.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.220
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.220
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019441 0 0 0 0 0 0 0 0 0 9 125 307
2019/20201.205 78 40 23 78 123 214 244 168 113 56 53 15
2020/20211.185 114 30 77 159 152 112 80 90 70 112 86 103
2021/2022628 80 22 23 36 15 45 13 49 62 76 129 78
2022/2023727 87 80 40 59 105 80 16 75 86 9 46 44
2023/2024229 9 16 10 45 65 2 33 40 3 6 0 0
Totale 4.482